Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 versus physician's choice chemotherapy in second-line HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20211583Phase 3Active
- Sponsor
- NovoCodex Biopharmaceuticals
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anvatabart opadotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by NovoCodex Biopharmaceuticals. Started Aug 2021; status: active.
02
Drugs
anvatabart opadotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20211583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211583.